KR20260098023A - Cd163 항체 또는 결합 단백질 - Google Patents

Cd163 항체 또는 결합 단백질

Info

Publication number
KR20260098023A
KR20260098023A KR1020267019563A KR20267019563A KR20260098023A KR 20260098023 A KR20260098023 A KR 20260098023A KR 1020267019563 A KR1020267019563 A KR 1020267019563A KR 20267019563 A KR20267019563 A KR 20267019563A KR 20260098023 A KR20260098023 A KR 20260098023A
Authority
KR
South Korea
Prior art keywords
sequence
antibody
amino acid
heavy chain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267019563A
Other languages
English (en)
Korean (ko)
Inventor
찰스 오웬
하피드 압델라리 벤차위
크리스틴 테이트-버카드
Original Assignee
에코 애니몰 헬스 엘티디
에코 애니몰 헬스 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에코 애니몰 헬스 엘티디, 에코 애니몰 헬스 엘티디 filed Critical 에코 애니몰 헬스 엘티디
Publication of KR20260098023A publication Critical patent/KR20260098023A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020267019563A 2019-12-24 2020-12-24 Cd163 항체 또는 결합 단백질 Pending KR20260098023A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1919294.7 2019-12-24
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
KR1020227025626A KR20220119147A (ko) 2019-12-24 2020-12-24 Cd163 항체 또는 결합 단백질
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025626A Division KR20220119147A (ko) 2019-12-24 2020-12-24 Cd163 항체 또는 결합 단백질

Publications (1)

Publication Number Publication Date
KR20260098023A true KR20260098023A (ko) 2026-06-25

Family

ID=69322779

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267019563A Pending KR20260098023A (ko) 2019-12-24 2020-12-24 Cd163 항체 또는 결합 단백질
KR1020227025626A Ceased KR20220119147A (ko) 2019-12-24 2020-12-24 Cd163 항체 또는 결합 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227025626A Ceased KR20220119147A (ko) 2019-12-24 2020-12-24 Cd163 항체 또는 결합 단백질

Country Status (13)

Country Link
US (1) US20230203185A1 (enExample)
EP (1) EP4081542A1 (enExample)
JP (1) JP7702952B2 (enExample)
KR (2) KR20260098023A (enExample)
CN (2) CN115151569B (enExample)
BR (1) BR112022012362A2 (enExample)
CL (1) CL2022001706A1 (enExample)
CO (1) CO2022010294A2 (enExample)
DO (2) DOP2022000136A (enExample)
GB (1) GB201919294D0 (enExample)
MX (1) MX428622B (enExample)
PE (1) PE20230384A1 (enExample)
WO (1) WO2021130502A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
JP2026519901A (ja) * 2023-01-27 2026-06-19 ヴィーアイビー ヴィーゼットヴィー Ｃｄ１６３結合複合体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076501A2 (en) * 2001-03-26 2002-10-03 Hemosol Inc. Blood cell production via activation of the hemoglobin scavenger receptor
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20160158368A1 (en) * 2014-10-31 2016-06-09 Therapure Biopharma Inc. Methods and compositions for the treatment of histiocytosis
HRP20240908T1 (hr) * 2015-08-06 2024-10-25 The Curators Of The University Of Missouri Svinja i stanice otporne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modificirane cd163 gene
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
JP2023508674A (ja) 2023-03-03
CO2022010294A2 (es) 2022-10-31
US20230203185A1 (en) 2023-06-29
PE20230384A1 (es) 2023-03-06
CN115151569A (zh) 2022-10-04
BR112022012362A2 (pt) 2022-09-06
CN121873247A (zh) 2026-04-17
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CL2022001706A1 (es) 2023-05-26
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
KR20220119147A (ko) 2022-08-26
CA3162664A1 (en) 2021-07-01
MX428622B (es) 2025-11-13
CN115151569B (zh) 2026-05-01
EP4081542A1 (en) 2022-11-02
JP7702952B2 (ja) 2025-07-04
GB201919294D0 (en) 2020-02-05

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000